 Nevro Corp NYSE: NVRO posted second-quarter revenue of 102.3 million, 81 YY, missing the consensus of 107.7 million. Total U.S. permanent implant procedures increased 60, while trial procedures increased 45, but when compared to Q2 FY19, implant procedures were up 5, and trial procedures decreased 8. 